Juno Therapeutics, a subsidiary of Bristol Myers Squibb, is at the forefront of developing CAR T cell therapies, which are investigational treatments not yet approved by the FDA. The company focuses on leveraging advanced scientific research to create transformative medical solutions. Juno operates in the biotechnology sector, primarily serving patients with severe medical conditions that require innovative treatment options. The business model revolves around extensive research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through partnerships, licensing agreements, and future sales of approved treatments. The company is committed to challenging conventional wisdom, pushing the boundaries of scientific discovery, and acting with urgency to meet the needs of patients.

Keywords: CAR T cell, biotechnology, investigational therapies, FDA, research, clinical trials, innovation, medical solutions, partnerships, commercialization.